A
5.02
0.27 (5.68%)
| Previous Close | 4.75 |
| Volume | 27,845 |
| Price / Sales | 1.57 |
| Price / Book | 0.930 |
| 52 Weeks Range |
| Operating Margin (TTM) | -6,187.46% |
| Diluted EPS (TTM) | -17.47 |
| Quarterly Revenue Growth (YOY) | -68.50% |
| Total Debt/Equity (MRQ) | 6.76% |
| Current Ratio (MRQ) | 7.56 |
| Operating Cash Flow (TTM) | -78.91 M |
| Levered Free Cash Flow (TTM) | -44.94 M |
| Return on Assets (TTM) | -38.74% |
| Return on Equity (TTM) | -60.44% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Aligos Therapeutics, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 0.6 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Relative Valuation | NA |
| Financial Health | 0.0 |
| Macro Environment | -1.3 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | -0.13 |
Select this tab to load the latest available analysis.
|
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 10.44% |
| % Held by Institutions | 65.63% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Sio Capital Management, Llc | 30 Jun 2026 | 327,237 |
| Hhlr Advisors, Ltd. | 30 Jun 2026 | 76,247 |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |